Anti-inflammatory and anti-asthma treatment with reduced side effects
AssigneeSmithKline Beecham Corporation
InventorsMary S. Barnette, Theodore J. Torphy, Siegfried Benjamin Christensen, IV
Life of this patent
Estimating the term…
Abstract
This invention relates to a method for selecting PDE IV inhibitors which have a salutory therapeutic index, and to compounds having these properties.
Claims13
A method for dilating bronchi in a human by preferentially inhibiting the PDE IV catalytic form that binds R-rolipram with a low affinity, which method comprises administering to a subject in need thereof an effective amount of a compound having an IC.sub.50 ratio of about 0.1 or greater as regards the IC.sub.50 for PDE IV form which binds R-rolipram with a high affinity divided by the IC.sub.50 for the catalytic form which binds R-rolipram with a low affinity.
A method for elevating cAMP in leukocytes and airway smooth muscles while minimizing gastrointestinal and psychotropic effects in a human, which method comprises administering to a subject in need thereof an effective amount of a compound having an IC.sub.50 ratio of about 0.1 or greater as regards the IC.sub.50 for the PDE IV form which binds R-rolipram with a high affinity divided by the IC.sub.50 for the catalytic form which binds R-rolipram with a low affinity.
Dependencies are inferred from the claim text.